Novartis settles with licensee of blood cancer therapy day before trial

The pharma giant and biopharma company Incyte announce settlement of dispute over alleged unpaid royalties | News comes on eve of trial in Manhattan.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Patent cliff: 5 blockbusters running out of road

1 April 2025 MSD, Novartis and Eli Lilly are among those whose multi-billion-dollar patents are hurtling towards expiration, writes Marisa Woutersen.

Americas

Novartis and MSN feud intensifies after Fed Circ denies rehearing

27 March 2025 Both parties write to district court hours after Court of Appeals denies rehearing | MSN maintains that the Entresto patent should be delisted from the Orange Book | Novartis urges injunction to block generic version of heart treatment before regulatory gap closes.

Big Pharma

Novartis stops rival’s launch of Entresto generic

16 January 2025 A district court of appeal has paused MSN Pharmaceuticals’ launch | Result comes days after the Federal Circuit restored Novartis’ patent and overturned a decision in favour of MSN | Request is one in a flurry of filings between the pair over the heart-failure drug.

More features

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Novartis settles with licensee of blood cancer therapy day before trial

More on this story

Editor's picks

Editor's picks

More features